Welcome to our dedicated page for CASTLE BIOSCIENCES SEC filings (Ticker: CSTL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on CASTLE BIOSCIENCES's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into CASTLE BIOSCIENCES's regulatory disclosures and financial reporting.
Castle Biosciences’ president, chief executive officer and director reported multiple stock transactions tied to restricted stock unit (RSU) vesting. On December 9, 2025, RSUs converted into 33,495 shares of common stock, followed by the disposition of 13,181 shares at $38.25 per share to cover tax obligations. On December 10, 2025, additional RSUs converted into 15,424 shares, with 6,070 shares disposed of at $38.02 per share for taxes, leaving 67,215 shares of common stock held directly.
The reporting person also lists indirect beneficial ownership in Castle Biosciences common stock through several family and grantor retained annuity trusts, each holding separate blocks of shares for the benefit of the reporting person, spouse and children.
Castle Biosciences' Chief Commercial Officer reported equity transactions involving restricted stock units and common stock. On December 9, 2025 and December 10, 2025, the reporting person acquired 15,961 and 6,170 shares of common stock coded "M" in connection with restricted stock units, and disposed of 6,441 and 2,490 shares coded "F" at prices of $38.25 and $38.02 per share.
After these transactions, the officer beneficially owned 100,025 shares of Castle Biosciences common stock directly. The filing also shows 15,961 restricted stock units outstanding from a grant made on December 9, 2022 that vests in four equal installments beginning on December 9, 2023, and notes that 24,679 restricted stock units granted on December 10, 2021 vest in four equal installments beginning on December 10, 2022. The ownership total includes 2,230 shares that were previously held by a family revocable trust and were distributed to the reporting person on February 5, 2025.
Castle Biosciences Inc. reported an insider stock sale by a director who also serves as president and chief executive officer. On December 4, 2025, the insider sold 1,339 shares of common stock at a weighted-average price of $40.03 per share in a transaction made under a contract, instruction or written plan intended to satisfy Rule 10b5-1(c), which was adopted on May 8, 2025.
After this sale, the insider directly owned 37,547 shares of Castle Biosciences common stock and reported additional indirect holdings through several family trusts, including 52,923 shares held by The Maetzold Descendants 2020 Trust and 44,986 shares held by the Derek Maetzold 2020 Irrevocable Trust.
Castle Biosciences, Inc. reported an insider stock sale by a senior executive. The company’s president and chief executive officer, who is also a director, filed a Form 4 showing the sale of 5,115 shares of common stock on 11/25/2025 at a weighted-average price of $40.049 per share.
The filing states that this transaction was made under a pre-arranged Rule 10b5-1 trading plan adopted on May 8, 2025. Following the sale, the executive directly owns 45,822 shares of Castle Biosciences common stock. In addition, the executive reports indirect ownership through several family and grantor retained annuity trusts, including 52,923 shares held by The Maetzold Descendants 2020 Trust and 85,959 shares held by DJM Grantor Retained Annuity Trust No. 5, among other trust holdings.
Castle Biosciences (CSTL) reported insider activity by its Chief Commercial Officer. On 11/20/2025, the officer exercised a stock option to buy 4,693 shares of common stock at $3.38 per share and on the same day sold 4,693 shares in open-market transactions at a weighted-average price of $35.58, with individual trades ranging from $35.40 to $35.85. These trades were carried out under a Rule 10b5-1 trading plan adopted on September 11, 2024.
After the transactions and a 68-share reconciliation adjustment, the officer beneficially owns 84,595 shares directly and 2,230 shares indirectly through a family revocable trust. The officer also holds 11,210 fully vested stock options with a $3.38 exercise price expiring on March 12, 2029.
Castle Biosciences Inc. insider trading report: A reporting person who serves as a director and as President & Chief Executive Officer of Castle Biosciences (CSTL) sold 2,678 shares of common stock on 11/18/2025 at a weighted-average price of $34.02 per share. The sale was made pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on May 8, 2025. After this transaction, the insider directly holds 50,937 shares of common stock and also reports indirect ownership through multiple family and grantor retained annuity trusts, including 52,923 shares held by The Maetzold Descendants 2020 Trust and 44,986 shares held by the Derek Maetzold 2020 Irrevocable Trust.
Castle Biosciences (CSTL) reported insider transactions by its Chief Commercial Officer on an amended Form 4. On 11/11/2025, the officer exercised stock options at $3.38 and sold 500 shares at a weighted-average sale price of $35.39. On 11/12/2025, the officer exercised options at $3.38 and sold 200 shares at $35.40. These trades were made under a Rule 10b5-1 plan adopted on September 11, 2024.
Following the transactions, beneficial ownership was 84,527 shares direct and 2,230 shares indirect held by a family revocable trust. Derivative securities beneficially owned after the reported transactions were 15,903 stock options expiring on 03/12/2029. The amendment notes the option exercises were inadvertently omitted from the original filing and are now reported.
Castle Biosciences (CSTL) Form 4: Chief Financial Officer Frank Stokes reported an open-market sale of 5,388 shares of common stock on 11/11/2025 at a weighted-average price of $35.08. The filing notes multiple trades executed between $34.44 and $35.37. Following the transaction, Stokes beneficially owns 43,328 shares, held directly. The sale was made pursuant to a Rule 10b5-1 trading plan adopted on 08/12/2025.
Castle Biosciences (CSTL) reported an insider transaction by its Chief Commercial Officer on Form 4. The officer sold 500 shares of common stock on 11/11/2025 at a weighted-average price of $35.39 pursuant to a Rule 10b5-1 plan adopted on September 11, 2024. A separate sale of 200 shares occurred on 11/12/2025 at $35.40.
Following these transactions, the officer reported 84,027 shares held directly. In addition, 2,230 shares are held indirectly by the Tobin W and Susan M Juvenal Family Revocable Trust, of which the officer and spouse are trustees and beneficiaries include the officer, spouse, and their children.
Castle Biosciences (CSTL) reported an insider transaction by its Chief Operating Officer. On November 11, 2025, the COO sold 18,932 shares of common stock (code S) under a Rule 10b5-1 plan adopted on March 6, 2025 at a $35.10 weighted-average price, with trade prices ranging from $35.00 to $35.37.
Following the transactions, the reporting person beneficially owns 12,323 shares directly and 97,251 shares indirectly via The Fritz Shorter Trust. The filing also notes a transfer of 3,686 shares from the trust to direct holdings on November 11, 2025.